pembrolizumab
Showing 1 - 8 of 8
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Pembrolizumab
- +7 more
-
Beijing, Beijing, ChinaBeijing Tongren Hospital
Oct 26, 2023
Triple Negative Breast Cancer, Neoadjuvant Chemo, Pembrolizumab Trial in Seoul (Visium, Whole Genome Sequencing(WGS)/Whole
Recruiting
- Triple Negative Breast Cancer
- +3 more
- Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 15, 2023
Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT
Not yet recruiting
- Unresectable Hepatocellular Carcinoma
- +3 more
- Lenvatinib/Pembrolizumab plus SBRT combinations
-
Taipei City, Taiawn, TaiwanNational Taiwan University Hospital
Jan 30, 2023
NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +8 more
-
New Haven, ConnecticutYale University
Oct 26, 2022
Melanoma, Renal Cell Carcinoma, Brain Metastases Trial in New Haven (Pembrolizumab, Lenvatinib)
Recruiting
- Melanoma
- +6 more
-
New Haven, ConnecticutYale University
Feb 18, 2022
ESCC, Adjuvant Treatment, Lymph Node Positive Trial in Tianjin (Pembrolizumab Injection [Keytruda])
Recruiting
- ESCC
- +3 more
- Pembrolizumab Injection [Keytruda]
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Apr 26, 2021
Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemo, Pembrolizumab Trial in Tianjin (Pembrolizumab Injection
Recruiting
- Adenocarcinoma of Esophagogastric Junction
- +2 more
- Pembrolizumab Injection [Keytruda]
-
Tianjin, Tianjin, ChinaDepartment of minimally invasive esophageal surgery, Tianjin Med
Mar 22, 2021
Gut Microbiota, NSCLC, Pembrolizumab Trial (Pembrolizumab Combined With Chemotherapy)
Unknown status
- Gut Microbiota
- +3 more
- Pembrolizumab Combined With Chemotherapy
- (no location specified)
Apr 1, 2020